This transaction furthers Climb Bio’s goal of becoming a leader in developing new treatment options for immune-mediated diseases, complementing the Company’s anti-CD19 antibody, budoprutug.

The anti-CD19 mAb conjugated to a mayatansine derivative SAR3419, the anti-B cell lactosamine mAb mAref-216 and the anti-CD37 IgG fusion protein TRU-016 may be promising reagents for pediatric B ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the ...

Climb Bio (NASDAQ:CLYM – Get Free Report) is one of 1,061 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Climb Bio to ...

The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases ...